{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:42:36Z","timestamp":1791308556252,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Merit Review","award":["I01CX000320"],"award-info":[{"award-number":["I01CX000320"]}]},{"name":"Merit Review","award":["I01CX001156"],"award-info":[{"award-number":["I01CX001156"]}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jhep.2017.02.027","type":"journal-article","created":{"date-parts":[[2017,3,5]],"date-time":"2017-03-05T06:30:50Z","timestamp":1488695450000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma"],"prefix":"10.1016","volume":"67","author":[{"given":"Lauren A.","family":"Beste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela K.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Kogut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.02.027_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.29936","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132012, featuring the increasing incidence of liver cancer","author":"Ryerson","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2017.02.027_b0010","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.056","article-title":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001\u20132013","author":"Beste","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.02.027_b0015","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1001\/archinte.160.21.3227","article-title":"Risk factors for the rising rates of primary liver cancer in the United States","volume":"160","author":"El-Serag","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2017.02.027_b0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.02.027_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.027_b0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.02.027_b0035","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"issue":"100\u2013107","key":"10.1016\/j.jhep.2017.02.027_b0040","first-page":"e101","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.02.027_b0045","unstructured":"AASLD\/IDSA\/IAS\u2013USA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. [cited 10\/9\/2015]; Available from: http:\/\/www.hcvguidelines.org."},{"key":"10.1016\/j.jhep.2017.02.027_b0050","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0055","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0060","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jgh.12925","article-title":"Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor","volume":"30","author":"Kanogawa","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hep.26300","article-title":"Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma","volume":"58","author":"Hsu","year":"2013","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jhep.2017.02.027_b0070","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/jmv.24173","article-title":"Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma\u2014a retrospective multicenter study","volume":"87","author":"Harada","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2017.02.027_b0075","first-page":"6963","article-title":"Favorable prognosis in patients with sustained virological response to antiviral therapy, including interferon, for chronic hepatitis C before hepatic resection for hepatocellular carcinoma","volume":"35","author":"Shirabe","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhep.2017.02.027_b0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.02.027_b0085","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0095","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts","volume":"65","author":"Pol","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0100","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2016.06.023","article-title":"Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma","volume":"65","author":"Yang","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0105","unstructured":"Corporate Data Warenouse (CDW). March 28, 2014 [cited Feb 2, 2016.]; Available from: http:\/\/www.hsrd.research.va.gov\/for_researchers\/vinci\/cdw.cfm."},{"key":"10.1016\/j.jhep.2017.02.027_b0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/epirev\/mxu002","article-title":"Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs","volume":"37","author":"Beste","year":"2015","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.jhep.2017.02.027_b0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2007.03572.x","article-title":"The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases","volume":"27","author":"Kramer","year":"2008","journal-title":"Alimentary pharmacol Therapeut"},{"key":"10.1016\/j.jhep.2017.02.027_b0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1572-0241.2005.40670.x","article-title":"The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. Veterans with hepatitis C","volume":"100","author":"Kramer","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.02.027_b0125","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-154-2-201101180-00006","article-title":"Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States","volume":"154","author":"Davila","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.02.027_b0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hep.25800","article-title":"The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection","volume":"57","author":"Ioannou","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.02.027_b0140","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.gastro.2015.07.056","article-title":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001\u20132013","volume":"149","author":"Beste","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.02.027_b0145","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.mayocp.2016.06.009","article-title":"Racial disparities in inhospital outcomes for hepatocellular carcinoma in the United States","volume":"91","author":"Rajbhandari","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2017.02.027_b0150","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/ajg.2010.430","article-title":"Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study","volume":"106","author":"Kramer","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.02.027_b0155","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cgh.2010.07.012","article-title":"Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication","volume":"8","author":"Beste","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.02.027_b0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.21662","article-title":"Predictors of response of US veterans to treatment for the hepatitis C virus","volume":"46","author":"Backus","year":"2007","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1182\u20131188","key":"10.1016\/j.jhep.2017.02.027_b0165","first-page":"e1181","article-title":"Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection","volume":"140","author":"Kanwal","year":"2011","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2017.02.027_b0170","doi-asserted-by":"crossref","first-page":"B10","DOI":"10.2337\/diacare.27.suppl_2.B10","article-title":"Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data","volume":"27","author":"Miller","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2017.02.027_b0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.02.027_b0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.02.027_b0185","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdw219","article-title":"The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma","volume":"27","author":"Wirth","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2017.02.027_b0190","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiw457","article-title":"DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C","author":"Hengst","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2017.02.027_b0195","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hep.28334","article-title":"Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data","volume":"63","author":"Wilder","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.02.027_b0200","unstructured":"VIEKIRA PAK [package insert]. North Chicago, IL: AbbVie Inc. [cited August 8, 2016.]; Available from: https:\/\/www.viekirahcp.com\/."},{"issue":"457\u2013471","key":"10.1016\/j.jhep.2017.02.027_b0205","first-page":"e455","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.02.027_b0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.02.027_b0215","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jhep.2017.02.027_b0220","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817301265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817301265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T20:31:58Z","timestamp":1719088318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817301265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0168827817301265"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.02.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}